-
Mashup Score: 2T-DXd vs Physician’s Choice of Therapy in HER2-Positive Metastatic Breast Cancer: PROs in DESTINY-Breast02 - 1 day(s) ago
An analysis of patient-reported outcomes (PROs) in the DESTINY-Breast02 trial found that general health status/quality of life was maintained over time with fam-trastuzumab deruxtecan-nxki (T-DXd) vs …
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2
In a Dutch phase II study (TRAIN-3), researchers found that MRI detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-pos…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved - 14 day(s) ago
Recently, the FDA approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity following removal o…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 5
In the phase II PHERGain trial, researchers found that a positron-emission tomography (PET)-based, pathologic complete response (pCR)-adapted treatment strategy produced “excellent” 3-year invasive di…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2The Lancet Commission on Breast Cancer: Reducing Overlooked Inequities in Breast Cancer - 21 day(s) ago
Investigators have uncovered persistent inequities in breast cancer that may systematically leave many patients behind in spite of recent improvements in research, treatment, and survival, according t…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Breast Cancer With Sentinel Node Metastases: Axillary Dissection vs Sentinel Node Biopsy Alone - 23 day(s) ago
The phase III SENOMAC trial showed noninferiority in recurrence-free survival with sentinel node biopsy alone vs completion axillary node dissection in patients with breast cancer and sentinel node me…
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Gedatolisib Plus Palbociclib and Endocrine Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer - The ASCO Post - 1 month(s) ago
As reported in The Lancet Oncology by Layman et al, findings in dose-expansion groups of a phase Ib trial indicated activity of the pan-PI3K–mTOR inhibitor gedatolisib in combination with palbociclib and endocrine therapy in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The U.S. multicenter study included four dose-expansion groups with a total of 103 patients enrolled between December 2017 and June 2019: Group A: patients who were treatment-naive in the advanced
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2HR-Positive, HER2-Negative Metastatic Breast Cancer Treatment After Progression on CDK46 and Aromatase Inhibitors - The ASCO Post - 1 month(s) ago
In the phase II PACE trial reported in the Journal of Clinical Oncology, Erica L. Mayer, MD, MPH, and colleagues found no improvement in progression-free survival with the addition of palbociclib to fulvestrant—but a numeric improvement with the further addition of avelumab—in patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer whose disease progressed on prior CDK4/6 inhibitor and aromatase inhibitor treatment. In the U.S. multicenter open-label trial, 220 patients were
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3Gedatolisib Plus Palbociclib and Endocrine Therapy in HR-Positive, HER2-Negative Advanced Breast Cancer - The ASCO Post - 1 month(s) ago
As reported in The Lancet Oncology by Layman et al, findings in dose-expansion groups of a phase Ib trial indicated activity of the pan-PI3K–mTOR inhibitor gedatolisib in combination with palbociclib and endocrine therapy in patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancer. The U.S. multicenter study included four dose-expansion groups with a total of 103 patients enrolled between December 2017 and June 2019: Group A: patients who were treatment-naive in the advanced
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Giredestrant in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer - The ASCO Post - 1 month(s) ago
In the phase II acelERA BC trial reported in the Journal of Clinical Oncology, Miguel Martín, MD, PhD, and colleagues found that the selective estrogen receptor (ER) antagonist and degrader giredestrant did not significantly improve progression-free survival vs physician’s choice of endocrine therapy in previously treated patients with ER-positive, HER2-negative advanced breast cancer. In the open-label trial, 303 post-/pre-/perimenopausal women or men with measurable disease/evaluable bone lesions and
Source: ascopost.comCategories: General Medicine News, Onc News and JournalsTweet
T-DXd vs Physician’s Choice of Therapy in HER2-Positive Metastatic Breast Cancer: PROs in DESTINY-Breast02 https://t.co/ThedXnCDiZ #bcsm #breastcancer #oncology